Publications by authors named "Anna-Sophia Mast"
Article Synopsis
- Targeting acute myeloid leukemia (AML) with CAR-T cells is complex due to the widespread expression of AML antigens in healthy cells and the variability between different patients and even within the same patient's tumor cells.
- Single-cell analysis of 30 pediatric AML samples highlighted CD33, CD38, CD371, IL1RAP, and CD123 as key antigens, underscoring the need for multiple targeting strategies.
- The study introduces a modular Adapter CAR platform that allows for flexible and effective targeting of these antigens, showing that combining targets can lead to better treatment outcomes in heterogeneous AML populations.
Article Synopsis
- - The study examines the impact of COVID-19 on children with intestinal failure (IF), highlighting that out of 127 patients, 25 contracted the virus, with many experiencing gastrointestinal symptoms and a notable portion requiring hospitalization.
- - Vaccination appears to reduce the risk of gastrointestinal dysfunction, as only 25% of vaccinated children showed GI issues compared to 52% of unvaccinated ones.
- - Both IF patients and their caregivers reported a significant decline in quality of life due to pandemic restrictions, with caregivers of these patients experiencing a notably higher burden related to healthcare access and support.
The global COVID-19 pandemic forced changes in everyday life of children and adolescents due to government containment measures, an altered healthcare accessibility and utilization, and public concern about SARS-CoV-2 transmission. Data on the challenges and impact on children and their families with chronic diseases are limited. The primary objectives of this study were to assess (i) concerns for SARS-CoV-2 infection, (ii) perceived effects on health-related and overall quality of life (HRQoL and QoL), and (iii) accessibility and utilization of healthcare, comparing families with chronically ill children to families with healthy children during the second SARS-CoV-2 infection wave in Germany.
View Article and Find Full Text PDFCD19CAR T cells facilitate a transformational treatment in various relapsed and refractory aggressive B-lineage cancers. In general, encouraging response rates have been observed in B-lineage-derived non-Hodgkin's lymphomas treated with CD19CAR T cells. The major cause of death in heavily pretreated NHL patients is lymphoma progression and lymphoma recurrence.
View Article and Find Full Text PDFChimeric antigen receptor (CAR)-T therapy holds great promise to sustainably improve cancer treatment. However, currently, a broad applicability of CAR-T cell therapies is hampered by limited CAR-T cell versatility and tractability and the lack of exclusive target antigens to discriminate cancerous from healthy tissues. To achieve temporal and qualitative control on CAR-T function, we engineered the Adapter CAR (AdCAR) system.
View Article and Find Full Text PDFImmunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
Front Immunol
October 2021
Haploidentical stem cell transplantation (haplo SCT) in Stage IV neuroblastoma relapsed patients has been proven efficacious, while immunotherapy utilizing the anti-GD2 antibody dinutuximab beta has become a standard treatment for neuroblastoma. The combinatorial therapy of haplo SCT and dinutuximab may potentiate the efficacy of the immunotherapy. To gain further understanding of the synergistic effects, functional immunomonitoring was assessed during the clinical trial CH14.
View Article and Find Full Text PDF